Distribution of unfavorable cytogenetic abnormalities among the 186 patients, CR rate, and outcome
| Cytogenetic abnormalities . | N . | CR rate (95% CI) . | 2-year OS (95% CI) . |
|---|---|---|---|
| 3q abnormalities | 15 | 53% (25-81) | 7% (1-13) |
| del(5q) | 55 | 41% (28-54) | 7% (4-10) |
| −5 | 30 | 43% (25-61) | 6% (2.5-9.5) |
| del(7q) | 30 | 50% (32-68) | 16% (12-20) |
| −7 | 46 | 48% (33-63) | 12% (6-18) |
| 11q23/MLL except t(9;11) | 9 | 33% (0-83) | 11% (1-21) |
| t(6;9) | 3 | 100% (0-100) | 33% (6-60) |
| CK (≥ 3 abnormalities) | 129 | 39% (29-49) | 12% (9-15) |
| CK5 (≥ 5 abnormalities) | 91 | 38% (28-48) | 6% (3.5-8.5) |
| Cytogenetic abnormalities . | N . | CR rate (95% CI) . | 2-year OS (95% CI) . |
|---|---|---|---|
| 3q abnormalities | 15 | 53% (25-81) | 7% (1-13) |
| del(5q) | 55 | 41% (28-54) | 7% (4-10) |
| −5 | 30 | 43% (25-61) | 6% (2.5-9.5) |
| del(7q) | 30 | 50% (32-68) | 16% (12-20) |
| −7 | 46 | 48% (33-63) | 12% (6-18) |
| 11q23/MLL except t(9;11) | 9 | 33% (0-83) | 11% (1-21) |
| t(6;9) | 3 | 100% (0-100) | 33% (6-60) |
| CK (≥ 3 abnormalities) | 129 | 39% (29-49) | 12% (9-15) |
| CK5 (≥ 5 abnormalities) | 91 | 38% (28-48) | 6% (3.5-8.5) |